Abstract: Techniques are described with regard to managing transaction size during a database replication process. An associated computer-implemented method includes identifying each of at least one transaction associated with at least one source database stored in a replication capture memory, identifying at least one potential excessive memory transaction by applying, via at least one machine learning pattern detection model, pattern detection to each of the at least one transaction stored in the replication capture memory, and constructing at least one compact data unit associated with each of the at least one potential excessive memory transaction. The computer-implemented method further includes facilitating compact data unit transmission to a replication apply server system in order to replicate the at least one compact data unit associated with each of the at least one potential excessive memory transaction to at least one target database via a replication apply server application.

Abstract: The present application provides a recombinant fusion protein containing an anti-PD-L1 antibody or an antibody fragment thereof, with each paratope of the anti-PD-L1 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain variable region or a light chain variable region constituting the paratope, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over-expression of CD47 and/or PD-L1 using the recombinant fusion protein.

Abstract: Nitazoxanide represented by formula I and an active form thereof, tizoxanide compound, represented by formula II, a geometric isomer thereof and pharmaceutically acceptable salt thereof and/or solvate thereof and/or hydrate thereof, and a pharmaceutical composition containing this compound, used for preventing and/or treating coronavirus (such as SARS-CoV-2) infection.

Abstract: A use of ritonavir, or a geometric isomer, pharmaceutically acceptable salt, solvate, and/or hydrate thereof, and a pharmaceutical composition containing the above compound in treating a SARS-CoV-2 infections.

Abstract: A drug delivery system is described comprising a detachable support and a plurality of drug-loaded transdermal microneedles, for delivering drugs into gingival tissue for the treatment of periodontal disease.

Abstract: A display controller, comprising a 3D_LUT random access memory, which stores at least a 3D Lookup table; and a display control processing unit, comprising: a computing unit, a register, a color signal booster, and a color signal attenuator; wherein after input color signals are received by the color signal booster, and the color signal booster amplifies color signals by a first predetermined factor, wherein the computing unit calculates the address of the 3D Lookup table, and loads the 3D Lookup table from the 3D_LUT random access memory according to the register, wherein the color signal attenuator attenuates color signals by a second predetermined factor. The present disclosure significantly increases the precision of color conversion from one RGB color space to another RGB color space, and does not increase the RAM cost, since the cost of multiplying or dividing by power of 2, for example, is limited.

Abstract: A nitrogen-containing ring derivative regulator, a preparation method therefor and use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof as a G protein-coupled receptor regulator in the treatment or prevention of central nervous system diseases and/or mental diseases.

Abstract: The present invention relates to a vaginal drug delivery device configured to safely and effectively deliver a therapeutic formulation in the vagina at or near a desired target area for a specified time period.

Abstract: A rotary printing integrated ink box special for seal printing comprises an ink box body (1) with a cylindrical or elliptic cylindrical outer contour, a spray head (6) with a circuit board (5) is arranged outside the ink box body (1), the spray head (6) corresponds to an ink outlet (3), and contacts (7) connected with control lines of the spray head (6) are integrated on the circuit board (5); and a rotary fixed surface of the ink box body (1) is parallel to a rotary injection surface of the spray head (6).

Abstract: 2-Benzylidene hydrazinoadenosine compounds having A2A adenosine receptor agonistic activity, represented by a general Formula (I) and pharmaceutical compositions containing the same. The compounds and compositions can act as A2A adenosine receptor agonist to serve as medicaments.

Abstract: The present disclosure provides 6-hydrazinoadenosine represented by the general Formula (I) and its derivatives with A2A adenosine receptor agonist activity, and pharmaceutical compositions containing them. The compound and composition can be used as A2A adenosine receptor agonists and used as medicament.

Abstract: A multi-line laser radar includes a first radar component, where the first radar component includes n lasers, an optical collimating unit, a scanning rotating mirror, and a detector, where n is greater than 1. Each laser is configured to emit one laser beam to the optical collimating unit. The optical collimating unit is configured to collimate n laser beams, where the collimated n laser beams are incident on a target reflector of the scanning rotating mirror. The scanning rotating mirror includes m reflectors rotating around a rotation axis, where a rotation plane of the rotation axis is perpendicular to an arrangement direction of the collimated n laser beams, and m is greater than 1. The target reflector reflects the received collimated n laser beams to a detection area of the first radar component. The detector receives echo signals of the reflected n laser beams in the detection area.

Abstract: The present application provides a small-molecule compound, represented by general Formula (I), having A2A adenosine receptor antagonistic activity and a pharmaceutical composition containing same. The compound and composition can be used as A2A adenosine receptor antagonistic agents.

Abstract: The present invention discloses an adjustable gas detection device for coal bed comprising a detection direction adjustment assembly, a suction head angle adjustment assembly and an analysis bin, wherein the suction head angle adjustment assembly includes a suction head first-level angle adjustment assembly and a suction head second-level angle adjustment assembly, and the suction head first-level angle adjustment assembly includes a suction head that sucks a gas through a suction pump and sends it into the analysis bin through a suction pipe for analysis; the detection direction adjustment assembly and the suction head angle adjustment assembly jointly adjust a position and a direction of the suction head. The gas detection device for coal bed of the present invention has many degrees of freedom, can quickly complete the angle adjustment, and realizes rapidly-oriented detection, as well as having advantages of high control efficiency, rapid response, flexibility and reliability.

Abstract: Disclosed is a recombinant protein containing 1) an anti-PD-L1 antibody heavy chain and an anti-PD-L1 antibody light chain, which two are linked by a disulfide bond to bind PD-L1, and 2) an extracellular Ig-like domain of a vascular epithelial growth factor receptor (VEGFR), linked via a linker to the N-terminus or C-terminus of the heavy chain or the light chain, wherein the recombinant protein is capable of binding PD-L1, VEGF and Fc receptor simultaneously. Also disclosed are a recombinant antibody containing two recombinant proteins of the disclosure, a polynucleotide encoding the recombinant protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of VEGF and/or PD-L1 using the recombinant protein.

Abstract: Disclosed herein are an apparatus and method for generating a topological map for navigation of a robot. The method for generating a topological map for navigation of a robot, performed by the apparatus for building the topological map for the navigation of the robot, includes calculating the physical size of a single pixel on a metric map of a space in which a mobile robot is to navigate, extracting the physical coordinates of the pixel on the metric map, building node data and edge data for the navigation of the mobile robot using the physical coordinates, and generating a topological map for the navigation of the mobile robot based on the built node data and the built edge data.

Abstract: The present invention relates to a compound represented by Formula I, its pharmaceutically acceptable salt, its stereoisomer, its pharmaceutically acceptable hydrate or solvate, or its pharmaceutically acceptable ester, wherein R is selected from heteroaryl, substituted heteroaryl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, alkyl, and substituted alkyl, wherein the substituted heteroaryl, the substituted aryl, the substituted cycloalkyl and the substituted alkyl are each independently substituted with one or more hydroxyalkylene groups. The compound or its pharmaceutically acceptable salt, its stereoisomer, its pharmaceutically acceptable hydrate or solvate, its pharmaceutically acceptable ester of the present invention has agonistic activity on A2A adenosine receptor and can improve the permeability of blood-brain barrier to promote the delivery of drug across blood-brain barrier, and can also prevent or treat a disease associated with A2A adenosine receptor agonistic activity.

Abstract: A microparticle is described comprising an antigen and a costimulatory component derived from an antigen presenting cell. The microparticle may be used for stimulating T cells ex vivo, followed by administration to a subject, e.g., as part of a personalized, customized therapeutic treatment of cancer or a tumor, an autoimmune disease or an allergic reaction, hypersensitivity reaction, an infection or infectious disease, an injury or other damage, a transplant or other surgical site, or a blood clot. It may also be used for the controlled release of a cytokine for the regulation of immunity in general and for other therapeutic uses. Methods of treating a disease or medical condition in a subject by exposing leukocytes from the subject to the microparticle, then reinfusing the leukocytes into the subject are provided. Methods of preparing an activated cytotoxic T cell population specific for an antigen are also provided.

Abstract: An intelligent seal with cloud computing-based anti-forgery capability and a method for using the same. In various embodiments, the seal is provided with a special-shaped anti-forgery mark. All data files and log files are stored collectively at a seal management cloud platform, thereby achieving anti-forgery through cloud computing at the cloud platform, preventing theft and tampering of user data and seal data, allowing real-time query of seal usage information, and enabling third-party verification and anti-forgery of the seal information.

Abstract: A discharging control method and a charging control method for a rechargeable battery, and the rechargeable battery. An electric system of the rechargeable battery comprises a lithium ion cell and a discharging control circuit, and a charging control circuit. A positive electrode of the lithium ion cell is electrically connected to a common ground end (GND) of the charging and/or discharging control circuit, so that the common ground end (GND) serves as a positive electrode (P) of the charging input and/or discharging output of the rechargeable battery; a negative electrode of the lithium ion cell is electrically connected to an output end of the charging control circuit and an input end of the discharging control circuit; and the input end of the charging control circuit and the output end of the discharging control circuit are electrically connected to a negative electrode (N) of the rechargeable battery.